Efficacy of Daratumumab to Overcome Platelet Transfusion Refractoriness in Patients With Aplastic Anemia
Status:
Recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
This is a phase 1, prospective, single-arm, open-label study. The aim of this study is to
evaluate the transfusion responses of platelet increment by using Daratumumab among aplastic
anemia patients with platelet transfusion refractoriness.